Vinorebine, Everolimus + Vinorelbine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Her2-negative Metastatic Breast Cancer
Conditions
Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
Trial Timeline
Jan 1, 2012 → Oct 31, 2016
NCT ID
NCT01520103About Vinorebine, Everolimus + Vinorelbine
Vinorebine, Everolimus + Vinorelbine is a phase 2 stage product being developed by Novartis for Her2-negative Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01520103. Target conditions include Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01520103 | Phase 2 | Completed |
Competing Products
19 competing products in Her2-negative Metastatic Breast Cancer